VITAMIN D-GHRELIN CONJUGATES
    3.
    发明申请
    VITAMIN D-GHRELIN CONJUGATES 有权
    维生素D-GHRELIN结合物

    公开(公告)号:US20150065420A1

    公开(公告)日:2015-03-05

    申请号:US14542581

    申请日:2014-11-15

    CPC classification number: A61K47/60 A61K38/22 A61K47/551

    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

    Abstract translation: 本发明提供增强Ghrelin肽的吸收,半衰期或生物利用度的载体。 载体包含结合维生素D结合蛋白(DBP)的靶向基团,用于将靶向基团偶联到治疗化合物的缀合基团,以及任选的支架部分。

    Long-acting parathyroid hormone
    4.
    发明授权

    公开(公告)号:US12233115B2

    公开(公告)日:2025-02-25

    申请号:US18368347

    申请日:2023-09-14

    Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.

    RNAi VITAMIN D CONJUGATES
    8.
    发明申请
    RNAi VITAMIN D CONJUGATES 有权
    RNAi维生素D结合物

    公开(公告)号:US20160114049A1

    公开(公告)日:2016-04-28

    申请号:US14919671

    申请日:2015-10-21

    CPC classification number: A61K47/551 A61K31/00 A61K31/713 A61K47/60

    Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.

    Abstract translation: 本发明提供与治疗性RNA化合物缀合的非激素维生素D,当与非共轭形式相比时,其导致具有增加的吸收,生物利用度或循环半衰期的化合物。 维生素D靶向组通过维生素D主链上的第三个碳原子与治疗性RNA化合物偶联。

Patent Agency Ranking